<DOC>
	<DOCNO>NCT00752232</DOCNO>
	<brief_summary>The study evaluate safety , tolerability whether immune system response multiple dose ACC-001 without use substance may increase response drug .</brief_summary>
	<brief_title>Study Evaluating ACC-001 Japanese Patients With Mild To Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<criteria>Diagnosis mild moderate Alzheimer 's Disease Mini Mental Status Exam ( MMSE ) 1626 Significant Neurological Disease Major Psychiatric Disorder Clinically significant systemic illness</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Phase IIa</keyword>
	<keyword>multiple ascend dose study ACC-001</keyword>
</DOC>